Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
October 4, 2021
RegMed Investors’ (RMi) closing bell: sector was under heavy pressure, with a muddy path forward for sector equities
October 1, 2021
RegMed Investors’ (RMi) closing bell: Back from the depths to close positive
September 30, 2021
RegMed Investors’ (RMi) closing bell: sector closes the month with a slip and fall
September 29, 2021
RegMed Investors’ (RMi) closing bell: called it volatile and liquid this a.m., it was
September 28, 2021
RegMed Investors’ (RMi) closing bell: Déjà vu, the deep end
September 27, 2021
RegMed Investors’ (RMi) closing bell: risks are mounting as sentiment seems AWOL
September 24, 2021
RegMed Investors’ (RMi) closing bell: this morning’s “twitch” came to fruition
September 23, 2021
RegMed Investors’ (RMi) closing bell: lucky sector up day with low volume but, risk is still lurking
September 22, 2021
RegMed Investors’ (RMi) closing bell: back in the green after a volatile session
September 21, 2021
RegMed Investors’ (RMi) closing bell: a buying opportunity for the stem cell and gene therapy sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors